Christopher Weil

Peer-Reviewed Articles

1. Gravbrot N, Rock CB, Weil CR, Rock CB, Burt LM, DeCesaris CM, Jensen RL, Shrieve DC, Cannon DM. Gross tumor and intracranial control benefits with fractionated radiotherapy compared to stereotactic radiosurgery for patients with WHO grade 2 meningioma. World Neurosurg 188:e259-e266, 2024. e-Pub 2024. PMID: 38777319.
2. Gaffney D, Suneja G, Weil C, Creutzberg C. International Federation of Gynecology and Obstetrics Endometrial 2023 Is Better For Radiation Oncology Patients. Pract Radiat Oncol 14(6):574-581, 2024. PMID: 39019210.
3. Roach EA, Weil CR, Cannon G, Grant J, Van Meter M, Boothe D. The Role of Axillary Lymph Node Dissection versus Sentinel Lymph Node Dissection in Breast Cancer Patients with Clinical N2b-N3c Disease Who Receive Adjuvant Radiotherapy. Ann Surg Oncol 31(7):4527-4539, 2024. e-Pub 2024. PMID: 38647915.
4. Roach EA, Weil CR, Cannon G, Grant J, Van Meter M, Boothe D. ASO Visual Abstract: The Role of Axillary Lymph Node Dissection Versus Sentinel Lymph Node Dissection in Breast Cancer Patients with Clinical N2b-N3c Disease Who Receive Adjuvant Radiotherapy. Ann Surg Oncol. e-Pub 2024. PMID: 38769212.
5. Gravbrot N, Weil CR, DeCesaris CM, Gaffney DK, Suneja G, Burt LM. Corrigendum to "Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer" Eur. J. Cancer (201) (April) 2024, 113913. Eur J Cancer 202:114017, 2024. e-Pub 2024. PMID: 38570289.
6. Gravbrot N, Weil CR, DeCesaris CM, Gaffney DK, Suneja G, Burt LM. Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer. Eur J Cancer 201:113913, 2024. e-Pub 2024. PMID: 38377777.
7. Rock CB, Weil CR, Rock CB, Gravbrot N, Burt LM, DeCesaris C, Menacho ST, Jensen RL, Shrieve DC, Cannon DM. Patterns of failure after radiosurgery for WHO grade 1 or imaging defined meningiomas: Long-term outcomes and implications for management. J Clin Neurosci 120:175-180, 2024. e-Pub 2024. PMID: 38262262.
8. Hutten RJ, Weil CR, King AJ, Barney B, Bylund CL, Fagerlin A, Gaffney DK, Gill D, Scherer L, Suneja G, Tward JD, Warner EL, Werner TL, Whipple G, Evans J, Johnson SB. Multi-Institutional Analysis of Cancer Patient Exposure, Perceptions, and Trust in Information Sources Regarding Complementary and Alternative Medicine. JCO Oncol Pract 19(11):1000-1008, 2023. e-Pub 2023. PMID: 37722084.
9. Lee SS, Weil CR, Boyd LR, DeCesaris C, Gaffney D, Suneja G. Trends in use of radiation therapy, chemotherapy, and combination chemoradiotherapy in advanced uterine cancer before, during, and after GOG 258. Int J Gynecol Cancer 33(9):1408-1418, 2023. e-Pub 2023. PMID: 37487661.
10. Weil CR, Haroun F, Guo K, Humphries T, Zhao H, Burt LM, Suneja G, DeCesaris CM, Huang YJ, Gaffney DK. Importance of radiographic tumor regression during radiotherapy in squamous cell versus adenocarcinoma of the uterine cervix as assessed by MRI and cone beam CT. Eur J Gynaecol Oncol 44(1):68-78, 2023. PMID: None.
11. Rock CB, Hutten RJ, Weil CR, Lloyd S, Kerrigan KC, Cannon RB, Hitchcock YJ. Survival outcomes for patients with T3N0M0 squamous cell carcinoma of the glottis treated with definitive radiation alone versus chemoradiation. Head Neck 45(2):431-438, 2023. e-Pub 2022. PMID: 36433726.
12. Okwundu, N, Weil, CR, Soares, HP, Fine, GC, Cannon, DM. Case report. Frontiers in Nuclear Medicine 3, 2023. PMID: 39355023.
13. Weil CR, Parsons MJ, Hutten RJ, Lew FH, Johnson SB, Gaffney DK, Tao R. Patterns of care and outcomes of early stage I-II Hodgkin lymphoma treated with or without radiation therapy. Leuk Lymphoma 63(12):2847-2857, 2022. e-Pub 2022. PMID: 35904407.
14. Hutten RJ, Weil CR, Gaffney DK, Kokeny K, Lloyd S, Rogers CR, Suneja G. Racial and Ethnic Health Disparities in Delay to Initiation of Intensity-Modulated Radiotherapy. JCO Oncol Pract 18(10):e1694-e1703, 2022. e-Pub 2022. PMID: 35930751.
15. Kraus RD, Weil CR, Frances Su FC, Cannon DM, Burt LM, Mendez JS. Incidence and extent of disease progression on MRI between surgery and initiation of radiotherapy in glioblastoma patients. Neurooncol Pract 9(5):380-389, 2022. e-Pub 2022. PMID: 36134015.
16. Kraus R, Weil C, Abdel-Wahab M. Quality Assurance in Radiation Oncology: Addressing a Changing Treatment Landscape. Appl Radiat Oncol 11(1):32-34, 2022. e-Pub 2022. PMID: None.
17. Fenlon JB, Hutten RJ, Weil CR, Lloyd S, Cannon DM, Kerrigan K, Cannon RB, Hitchcock YJ. Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head Neck 44(3):606-614, 2022. e-Pub 2021. PMID: 34931386.
18. Weil CR, Lew FH, Williams VM, Burt LM, Ermoian RP, Poppe MM. Patterns of Care and Utilization Disparities in Proton Radiation Therapy for Pediatric Central Nervous System Malignancies. Adv Radiat Oncol 7(6):100868, 2022. e-Pub 2022. PMID: 36420204.
19. Hutten RJ, Weil CR, Gaffney DK, Kokeny K, Lloyd S, Rogers CR, Suneja G. Worsening Racial Disparities in Utilization of Intensity Modulated Radiation Therapy. Adv Radiat Oncol 7(3):100887, 2022. e-Pub 2022. PMID: 35360509.
20. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK. Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol 7(6):101035, 2022. e-Pub 2022. PMID: 36420188.
21. Kraus RD, Weil CR, Wells S, Tward JD, Groundland JS, Jones KB, Cannon DM. Radiation Therapy in Conjunction With Surgical Stabilization of Impending or Pathologic Fractures Secondary to Metastasis: Is There a Difference Between Single and Multifraction Regimens?. Adv Radiat Oncol 7(2):100795, 2022. e-Pub 2021. PMID: 35128177.
22. Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson SB. Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clin Genitourin Cancer 19(6):e360-e366, 2021. e-Pub 2021. PMID: 34130915.
23. Wheeler DA, Takebe N, Hinoue T, Hoadley KA, Cardenas MF, Hamilton AM, Laird PW, Wang L, Johnson A, Dewal N, Miller V, Pineyro D, Castro de Moura M, Esteller M, Shen H, Zenklusen JC, Tarnuzzer R, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn EC, Little RF, White J, Malik S, Harris L, Weil C, Chen AP, Karlovich C, Rodgers B, Shankar L, Jacobs P, Nolan T, Hu J, Muzny DM, Doddapaneni H, Korchina V, Gastier-Foster J, Bowen J, Leraas K, Edmondson EF, Doroshow JH, Conley BA, Ivy SP, Staudt LM. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell 39(1):38-53.e7, 2021. PMID: 33217343.
24. Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst 113(1):27-37, 2021. PMID: 32339229.
25. Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson SB. Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. Eur Urol Open Sci 23:30-33, 2021. e-Pub 2021. PMID: 34337486.
26. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst 112(10):1021-1029, 2020. PMID: 31922567.
27. Weil CR, Qian Y, Von Eyben R, Daadi SE, Corbelli KS, Rosenberg SA, Advani RH, Hoppe RT. Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation. Leuk Lymphoma 61(10):2428-2434, 2020. e-Pub 2020. PMID: 32476541.

Other Articles

1. Kraus RD, Weil CR, Abdel-Wahab M Benefits of Adopting Hypofractionated Radiotherapy as a Standard of Care in Low-and Middle-Income Countries. JCO Glob Oncol 8:e2200215, 2022. PMID: 36525619.
2. Rodriguez JA, Weil CR, Ramirez JF A Rare Cause of Cough: Tracheobronchial Myxoid Spindle Cell Lipoma. Case Rep Pulmonol 2020:9727281, 2020. PMID: 32551146.
3. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol 36(4):414-424, 2018. PMID: 29236593.

Abstracts

1. Weil CR, Cruttenden J, DeCesaris CM, Burt LM, Suneja G, MacEwan I, Poppe MM. Association between radiation dose and local failure in recurrent high-risk neuroblastoma. Int J Radiat Oncol Biol Phys, 2023. PMID: None.
2. Roach E, Avizonis V, Cannon G, Grant J, Van Meter M, Weil CR, Reading T, Boothe D. The role of tumor bed boost in breast cancer patients with HER2 positive disease treated with breast conversation therapy. Int J Radiat Oncol Biol Phys 117(2):E203-E204, 2023. PMID: None.
3. Roach E, Weil CR, Boothe D. The role of axillary lymph node dissection versus sentinel lymph node biopsy in women with undissected level II-III axillary nodes receiving radiotherapy. None, 2023. PMID: None.
4. Weil CR, Humphries T, Giraud-Carrier C, Boothe D. Machine learning to predict survival benefit from post-mastectomy radiotherapy in women with breast cancer with 1-3 positive lymph nodes. None, 2023. PMID: None.
5. Urias E, Weil CR, Tao R. Thoracic radiation does not increase cardiac-specific mortality in lymphoma patients. None, 2023. PMID: None.
6. Urias E, Lee J, Weil CR, Hashibe M, Maity A, Tao R. Safety and survival outcomes in patients with metastatic cancer treated with combined immune checkpoint inhibitors and ablative radiotherapy: a meta-analysis of prospective clinical trials. None, 2023. PMID: None.
7. Cruttenden J, Weil CR, Burt LM, Suneja G, Gaffney DK, DeCesaris CM. Addition of vaginal cuff brachytherapy boost to external beam radiation in FIGO stage II endometrial cancer: A National Cancer Database analysis of survival. None, 2023. PMID: None.
8. Foster-Palmer S, Weil CR, Burt LM. Access to radiation therapy and survival outcomes for endometrial cancer patients from small towns: A comparative study. None, 2023. PMID: None.
9. Rock CB, Hutten RJ, Weil CR, Lloyd S, Hitchcock Y. Survival outcomes for patients with T3N0M0 squamous cell carcinoma of the glottis treated with definitive radiation alone versus chemoradiation. Head Neck 45(2):431-438, 2022. PMID: 36433726.
10. Lee SS, Weil CR, Boyd L, Jr LM, Chino F, Gaffney DK, Shaikh F, Suneja G. Trends in IMRT Utilization for Definitive Treatment of Cervical Cancer, 2004-2018. Int J Radiat Oncol Biol Phys 114(3):E342-E343, 2022. PMID: None.
11. Weil CR, Hutten RJ, Barney B, Fagerlin A, Gaffney D, Gill D, Whipple G, Rhodes T, Scherer L, Suneja G, Tward JD, Werner T, Evans J, Johnson SB. Use Patterns and Perceptions of Non-Traditional Therapies in Radiotherapy Patients: Results from the Multi-Institutional Complementary and Alternative Medicine Exposure in Oncology (CAMEO) Study. JCO Oncol Pract 114(3):E449, 2022. PMID: None.
12. Weil CR, Hutten RJ, Barney B, Fagerlin A, Gaffney D, Gill D, Whipple G, Rhodes T, Scherer L, Suneja G, Tward JD, Werner T, Johnson SB, Evans J. Temporal trends of alternative therapy use before, during and after cancer treatment: Results from the multi-institutional Complementary and Alternative Medicine Exposure in Oncology (CAMEO) study. Int J Radiat Oncol Biol Phys 114(3):E459, 2022. PMID: None.
13. Lew FH, Weil CR, Rock CB, Rock CB, Burt LM, DeCesaris C, Jensen RL, Shrieve DC, Cannon DM. Effects of expansion size from gross tumor volume to planning target volume on control rates and patterns of recurrence in conventionally fractionated radiotherapy for WHO grade I meningiomas. Int J Radiat Oncol Biol Phys 114(3):e45-e46, 2022. PMID: None.
14. Haroun F, Weil CR, Guo K, Zhao H, Burt LM, Suneja G, DeCesaris C, Huang YJ, Gaffney DK. Importance of radiographic tumor regression during radiotherapy in squamous cell versus adenocarcinoma of the uterine cervix as assessed by MRI, CT and conebeam CT. Int J Radiat Oncol Biol Phys(114):3, 2022. PMID: None.
15. Hutten RJ, Weil CR, Gaffney DK, Kokeny K, Lloyd S, Rogers CR, Suneja G. Racial and ethnic disparities in delay to initiation of intensity-modulated radiotherapy. JCO Oncol Pract 18(10):e1694-e1703, 2022. PMID: 35930751.
16. Lee J, Cole S, Weil CR, White H, DeVries C. Off study utilization of an unpublished trial regimen: A real-world analysis of GOG258-eligible cohorts. JCO Oncol Pract 40(16), 2022. PMID: None.
17. Hardikar S, Weil CR, Lloyd S, Cohan JN, Supiano MA, Ose J, Peoples AR, Pelletier K, Extermann M, Siegel EM, Shibata D, Ulrich CM. Treatment patterns in stage I-III colorectal cancer patients over 65 years of age. Cancer Res 82(12):36, 2022. PMID: None.
18. Weil CR, Hutten RJ, Barney B, Fagerlin A, Gaffney D, Gill D, Whipple G, Rhodes T, Scherer L, Suneja G, Tward JD, Werner T, Johnson SB, Evans J. Shifting perceptions of alternative therapies in cancer patients during the COVID-19 pandemic: results from the Complementary and Alternative Medicine Exposure in Oncology (CAMEO) Study. JCO Oncol Pract 40(16), 2022. PMID: None.
19. Weil CR, Lew FH, Williams VM, Burt LM, Ermoian RP, Poppe MM. Patterns of Care and Utilization Disparities in Proton Radiation Therapy for Pediatric Central Nervous System Malignancies. Adv Radiat Oncol 7(6), 2022. PMID: 36420204.
20. Hutten RJ, Weil CR, Gaffney DK, Kokeny K, Shane L, Rogers CR, Suneja G. Worsening Racial Disparities in Utilization of Intensity Modulated Radiation Therapy. Adv Radiat Oncol 7(3), 2022. PMID: 35360509.
21. Lee S, Weil CR, Boyd L, DeCesaris CM, Gaffney DK, Suneja G. Off study utilization of an unpublished trial regimen: a real-world analysis of GOG258-eligible cohorts. None, 2022. PMID: None.
22. Kraus RK, Weil CR, Su FC, Cannon DM, Mendez K, Burt LM. Rapid early progression in glioblastoma patients: missing the target. None, 2022. PMID: None.
23. Weil CR, Poppe MM, DeCesaris CM. Patterns of care and outcomes in male breast cancer treated with mastectomy with or without post-mastectomy radiation relative to National Comprehensive Cancer Network (NCCN) guidelines. None, 2022. PMID: None.
24. Hutten RJ, Weil CR, Barney B, Fagerlin A, Gaffney D, Gill D, Whipple G, Rhodes T, Scherer L, Suneja G, Tward JD, Werner T, Evans J, Johnson SB. Complementary and alternative medicine exposure in oncology (CAMEO) study: A multi-institutional cross-sectional analysis of patients receiving cancer treatment. JCO Oncol Pract 40(16), 2022. PMID: None.
25. Hardikar S, Weil CR, Lloyd S, Cohan JN, Supiano MA, Ose J, Peoples AR, Gupta S, Pelletier K, Extermann M, Siegel EM, Shibata D, Ulrich CM. Survival outcomes in stage I-III colorectal cancer patients over 65 years of age: results from the National Cancer Database. None, 2022. PMID: None.
26. Kraus RD, Weil CR, Su FC, Burt LM, Mendez JS. Incidence and Extent of Disease Progression on MRI Between Surgery and Initiation of Radiotherapy in Glioblastoma Patients. Int J Radiat Oncol Biol Phys 111(3):e592-e593, 2021. PMID: None.
27. Weil CR, Lew FH, Gaffney DK, Suneja G, Williams VM. Patterns of practice for adjuvant treatment of FIGO 1B grade 3 endometrial adenocarcinoma following publication of ASTRO 2014 guidelines for postoperative treatment in women with early stage high risk endometrial cancer. Int J Radiat Oncol Biol Phys 111(3):e635, 2021. PMID: None.
28. Weil CR, Parsons MW, Chipman J, Kraus RD, Suneja G, Burt LM, Dood R, Gaffney DK. Secondary malignancy risk in cervical cancer survivors after 40 years of follow up stratified by treatment modality and radiation technique. Int J Radiat Oncol Biol Phys 111(13):e624, 2021. PMID: None.
29. Kraus R, Weil CR, Wells S, Tward JD, Cannon DM. Radiation Therapy in Conjunction With Surgical Stabilization of Impending or Pathologic Fractures Secondary to Metastasis: Is There a Difference Between Single and Multifraction Regimens?. Adv Radiat Oncol 7(2), 2021. PMID: 35128177.
30. Kraus RK, Parsons MW, Weil CR, Chipman J, Suneja G, Burt LM, Brackmann M, Gaffney DK. A report on the unique secondary malignancy risk profiles for uterine cancer patients stratified by treatment received: A SEER database study spanning 40 years. None, 2021. PMID: None.
31. Lee J, Cole S, Weil CR, White H, DeVries C. Telehealth in pediatric surgical care. None, 2021. PMID: None.
32. Lew FH, Weil CR, Rock CB, Kraus RD, Cannon DM, Jensen R, Burt LM. Patterns of care and treatment disparities in the management of benign central nervous system meningioma. None, 2021. PMID: None.
33. Weil CR, Hu B, Halwani A, Glenn M, Johnson SD, Gaffney DK, Wada D, Tao R. Outcomes of non- Hodgkin lymphomas treated with ultra-low dose radiation therapy. None, 2021. PMID: None.
34. Williams VM, Weil CR, Suneja G. Racial disparities in the receipt of brachytherapy for cervical cancer and the impact on treatment outcome. None, 2021. PMID: None.